Rory B. Riggs, Director at Royalty Pharma plc (RPRX), sold 704,800 shares at $27.79 ($19.7M) on 2024-01-03, disclosed to the SEC on 2024-01-04.
Scheduled sale ($19.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.52 | 235,200 | $6.7M | 34.0% |
| 2 | $27.79 | 199,098 | $5.5M | 28.0% |
| 3 | $27.79 | 199,098 | $5.5M | 28.0% |
| 4 | $27.55 | 35,702 | $984K | 5.0% |
| 5 | $27.55 | 35,702 | $984K | 5.0% |
| Total | $28.01 avg | 704,800 |
| $19.7M |
| 100% |
| Filing → |
| CBUS | BUY | 2023-06-02 | $32K | — | Filing → |
| RPRX | SELL | 2023-05-22 | $57.4M | — | Filing → |
| RPRX | SELL | 2023-03-30 | $10.2M | — | Filing → |